A Phase 2 Randomized Double-Blind Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis

Brief description of study

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called BMS-986165 as a possible treatment for ulcerative colitis. An experimental drug is one that is being tested and is not approved by the United States Food and Drug Administration (FDA). It is expected that this drug will work by blocking and inactivating a protein in the body that turns on the inflammation that leads to Crohn’s disease.


Clinical Study Identifier: s19-00098
ClinicalTrials.gov Identifier: NCT03934216
Principal Investigator: Blanche Fung Liu.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.